Cerivastatin = ( Baycol®, Lipobay®) Withdrawn from market by                 

                          BAYER due to toxicity
                
                 http://en.wikipedia.org/wiki/Cerivastatin

Fluvastatin  =  (Lescol®, Canef®)

                         http://en.wikipedia.org/wiki/Fluvastatin

Lovastatin   =  (Mevacor®, Advicor® (as a combination with                    

                          niacin), Altocor®, Altoprev®, Statosan® (Atos Pharma)
 
                          http://en.wikipedia.org/wiki/Lovastatin

Mevastatin   =  Mevastatin is not used in therapy of hyperlipidemias because 

                          of multiple side effects but it is the only source for       

                          production of another statin - pravastatin.                  

   
                          http://en.wikipedia.org/wiki/Mevastatin

Pitavastatin =  It has been available in Japan since 2003, and is being      

                         marketed under licence in South Korea and in India.[2] It is 

                         likely that pitavastatin will be approved for use in         

                         hypercholesterolaemia(elevated levels of cholesterol in the  

                         blood) and for the prevention of cardiovascular disease      

                         outside South and Southeast Asia as well. 

                         http://en.wikipedia.org/wiki/Pitavastatin

Pravastatin  = (marketed as Pravachol or Selektine)

                        http://en.wikipedia.org/wiki/Pravastatin

Rosuvastatin = (Crestor)
                
                        http://en.wikipedia.org/wiki/Rosuvastatin

Simvastatin  =  Zocor® Reference: Drug Discovery Today editorial, 2005.[7]

                          Simvastatin was initially marketed by Merck & Co under the    

                          trade name Zocor, but is now also available generically in    

                          most countries following the patent expiry. A combination of  

                          Simvastatin along with Ezetimibe is currently sold under the  

                          brand name Vytorin and is jointly marketed by Merck and       

                          Schering-Plough.

                          Brand names: Zocor®, Zocor Heart Pro®, marketed by the        

                          pharmaceutical company Merck & Co. and Denan (Germany),       

                          Liponorm, Sinvacor, Sivastin (Italy), Lipovas (Japan), Lodales

                          (France), Zocord (Austria and Sweden), Zimstat, Simvahexal    

                          (Australia), Lipex (Australia and New Zealand), Simvastatin-  

                          Teva, Simvacor, Simvaxon, Simovil (Israel), Simvotin (India)  

                           and others.

                          The primary US patent for Zocor expired on June 23, 2006;     

                          Ranbaxy Laboratories (at the 80-mg strength) and Teva         

                          Pharmaceutical Industries through its Ivax Pharmaceuticals    

                          unit (at all other strengths) were given approval by the FDA  

                          to manufacture and sell simvastatin as a generic drug with    

                         180-day exclusivity. Dr. Reddy's Laboratories also has a      

                         license from Merck & Co. to sell simvastatin as an authorized 

                         generic drug.

                         Ezetimibe/simvastatin is a combination product to lower lipids

                         and marketed as Vytorin.

                         http://en.wikipedia.org/wiki/Simvastatin

Statins In The News:

The Cholesterol Con -- Where Were the Doctors?
By Maggie Mahar, Health Beat. Posted February 29, 2008.

http://www.alternet.org/healthwellness/77916/

Do Cholesterol Drugs Do Any Good? Cover Story January 17, 2008, 10:00AM EST
Research suggests that, except among high-risk heart patients, the benefits

of statins such as Lipitor are overstated
by John Carey

  http://www.businessweek.com/magazine/content/08_04/b4068052092994.htm